If Ozempic and Wegovy taught the world that one drug can wear two names, Zepbound and Mounjaro are the exact same story told again — this time with tirzepatide. They are a single molecule sold under two brands for two approved purposes. So the real question is not “which is stronger” but “why are there two names, and which one applies to me?”
The Same Drug, Two Names
Both Zepbound and Mounjaro are brand names for tirzepatide, made by Eli Lilly. The active molecule is identical: a dual agonist that activates both the GLP-1 and GIP receptors, which is what makes tirzepatide more potent than single-receptor GLP-1 drugs like semaglutide. Same compound, same weekly injection, same mechanism — just two labels.
This mirrors the Ozempic-versus-Wegovy situation almost exactly, and the lesson is the same: the branding implies a difference in the drug that does not exist. Whatever separates Zepbound and Mounjaro, it is not the tirzepatide inside them.
The Real Differences
The differences are in the paperwork, not the pharmacology. Mounjaro is approved for type 2 diabetes, where the goal is blood-sugar control. Zepbound is approved for chronic weight management in obesity — and has also gained approval for obstructive sleep apnea in adults with obesity, a notable expansion. Both are the same tirzepatide, titrated upward over time, and both deliver the appetite reduction and weight loss tirzepatide is known for. The split is indication, branding, and often insurance coverage.
For how tirzepatide itself compares with its rivals, our retatrutide vs tirzepatide and tirzepatide vs semaglutide guides go deep. The short version: tirzepatide (either brand) sits above semaglutide and below retatrutide in trial potency.
Zepbound and Mounjaro are the same molecule — tirzepatide. Like Wegovy and Ozempic, the difference is the label and the approved use, not the drug.The one-drug-two-brands pattern, again
Why There Are Two Names
The two-brand strategy is deliberate, and it follows the same logic Novo Nordisk used with semaglutide. Launching a diabetes brand (Mounjaro) and a separate obesity brand (Zepbound) lets the manufacturer pursue distinct approvals, pricing, and insurance pathways for each use, even though the molecule is one and the same. It also helps separate the diabetes and weight-management markets in the eyes of prescribers and payers.
For patients, the upshot is familiar confusion: people hear both names, assume they are different medications, and wonder which is “better.” In reality the choice is dictated by which condition is being treated and which brand a given insurer will cover — not by any difference in the drug. This is the tirzepatide version of the Ozempic vs Wegovy mix-up.
Which One Is Prescribed When
The pattern tracks the approvals cleanly. A person with type 2 diabetes is typically prescribed Mounjaro, with weight loss as a welcome secondary effect. A person whose goal is weight management, without diabetes, is the intended Zepbound patient — and if obstructive sleep apnea with obesity is in the picture, Zepbound now has specific standing there too. Coverage frequently decides the rest, since a diabetes drug and an obesity drug can be reimbursed very differently even when identical.
To see where both fit among all the options, the GLP-1 weight-loss drugs guide is the hub, and Mounjaro vs Ozempic compares across manufacturers rather than within one.
Explore tirzepatide, the full GLP-1 class, and the research behind each compound in the TrueLabs library.
FAQ
Tap a question to reveal the answer.
Are Zepbound and Mounjaro the same drug?
Yes. Both are brand names for tirzepatide, made by Eli Lilly. The active molecule, a dual GIP and GLP-1 agonist, is identical in both. The differences are the approved use and the branding, not the drug itself.
Is Zepbound stronger than Mounjaro?
No. They contain the same tirzepatide at the same available doses. Neither is inherently stronger; any difference in results comes from the dose a person is on and why they are taking it, not from the brand on the box.
What is the difference between Zepbound and Mounjaro?
Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in obesity and, more recently, for obstructive sleep apnea in adults with obesity. The tirzepatide inside is the same; the approved indications, branding, and insurance coverage differ.
Can you lose weight on Mounjaro?
Yes. Because Mounjaro is tirzepatide, it produces the same appetite reduction and weight loss as Zepbound, which is why it is often used off-label for weight management. The difference is that Zepbound is the version formally approved for that purpose.
Which is approved for weight loss, Zepbound or Mounjaro?
Zepbound is the weight-management brand; Mounjaro is the diabetes brand. If weight loss is the on-label goal, Zepbound is the approved choice. In practice, availability and insurance coverage often determine which brand a person actually receives.
Is tirzepatide better than Ozempic?
In head-to-head research, tirzepatide produced greater weight loss than semaglutide (the drug in Ozempic and Wegovy). That applies whether the tirzepatide is branded Zepbound or Mounjaro, since they are the same molecule. Our tirzepatide vs semaglutide guide covers the trial data in detail.
Do Zepbound and Mounjaro have the same side effects?
Yes, because they are the same drug. Both most commonly cause gastrointestinal effects such as nausea, and both carry the same warnings. Differences in how often side effects occur usually reflect the dose rather than the brand.
Related reading
- Ozempic vs Wegovy
- Retatrutide vs tirzepatide
- Tirzepatide vs semaglutide
- Mounjaro vs Ozempic
- GLP-1 weight-loss drugs guide
References
- FDA prescribing information for Mounjaro and Zepbound (tirzepatide), including indications.
- Jastreboff AM, et al. Tirzepatide once weekly for obesity, SURMOUNT-1. New England Journal of Medicine, 2022.
- Eli Lilly product information, tirzepatide indications including obstructive sleep apnea.
This article is informational and summarizes public information. It is not medical advice, a treatment protocol, or dosing guidance. Prescription medications should be used only under a licensed clinician, and any research compounds referenced are for laboratory use only. Always consult the current scientific literature and comply with local regulations.